BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
No, that's a great question. And right now what I'm doing is I do offer them cisplatinum-based chemotherapy if they did not receive it and they were eligible. But again, if they refuse it in the neoadjuvant setting, they're probably going to refuse it in the adjuvant setting.
0
💬
0
Comments
Log in to comment.
There are no comments yet.